Zydus Lifesciences Limited (ZYDUSLIFE) has announced that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda®. This marks the first publicly announced acceptance by the USFDA of an application for a Keytruda® biosimilar. The BLA was submitted in the third quarter of 2026.

Significant Milestone

The acceptance of the application is a significant step toward expanding access to affordable pembrolizumab therapy in the U.S. and Canada. The regulatory dossier for FYB206 has also been submitted to Health Canada. This development is expected to improve patient access and outcomes in oncology treatment.

Development Pathway

FYB206 was developed without a comparative Phase III efficacy trial, following a development pathway agreed upon with the USFDA in early 2025. Zydus holds exclusive commercialization rights for the United States and Canada and brings extensive commercial experience in the North American market for this product.

Future Outlook

Under the Biosimilar User Fee Amendments (BsUFA), the USFDA aims to complete its review within twelve months of submission. A decision could be expected in the third quarter of 2027. With this milestone, Zydus and Formycon aim to make this important cancer therapy accessible to more patients.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 75% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Max India Limited (MAXIND) has launched the SCALE initiative in collaboration with the Max Institute of Healthcare Management (MIHM) at the Indian School of Business (ISB) and Antara Senior Care to advance senior-care research. The SCALE initiative aims to bridge research and industry experience to develop scalable solutions for India’s rapidly growing senior population.

Addressing the Gap in Senior-Care Research

India is witnessing an increasing demand for senior care that is accessible, appropriate, and sustainable. However, these learnings remain fragmented. The SCALE Initiative seeks to address this gap by generating evidence and translating it into insights that can assist industry stakeholders and policymakers to make informed decisions.

Focus Areas of the SCALE Initiative

The initiative will focus on consumer behavior, workforce participation, social inclusion, operating and care delivery models, and technology adoption. Antara Senior Care, as the founding industry partner, is supporting SCALE’s engagement with the senior care sector.

Future of Senior Care in India

SCALE will bring together researchers, senior care industry stakeholders, and clinicians to examine the evolving care needs of seniors and identify priority action areas. The initiative aims to build an industry-level evidence base to help organizations innovate, respond to evolving consumer needs, make informed business and investment decisions, strengthen workforce strategies, and scale effective approaches.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 6.6% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.

Zydus Lifesciences Limited (NSE: ZYDUSLIFE) has unveiled new post hoc analysis from the pivotal Phase 3 EPICS-III trial of saroglitazar, showing greater biochemical response compared to placebo across geographic subgroups in patients with primary biliary cholangitis (PBC). The findings were presented at the American College of Gastroenterology (ACG) 2026 Annual Meeting.

Greater Biochemical Response in U.S. Subgroup

Numerically higher biochemical response treatment difference was observed in the U.S. subgroup relative to the non-U.S. subgroup (∆ 60.7% vs. ∆ 41.6%) in patients with PBC. These results build on the clinical profile of saroglitazar in patients with PBC who have inadequate response or intolerance to ursodeoxycholic acid (UDCA).

EPIC-III Trial Overview

The EPICS-III trial is a multicenter, randomized, double-blind, placebo-controlled, seamless Phase 2(b)/3 trial evaluating the efficacy and safety of saroglitazar in patients with PBC who had an inadequate response to or intolerance of UDCA. The trial included nearly thirty percent of patients from the U.S. and composite biochemical response rates were greater with saroglitazar than placebo in both U.S. (60.7% vs. 0%) and non-U.S. subgroup regions (55.1% vs. 13.5%). Saroglitazar was generally well tolerated, with adverse events generally balanced between saroglitazar-treated and placebo-treated patients.

As a result, Zydus Therapeutics plans to launch saroglitazar in the United States by March 2027 if approved by the FDA. These findings provide additional insight into the Phase 3 EPICS-III results and the biochemical responses observed among patients enrolled in different geographic regions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 75% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.